Analysis of US Patent 12,358,870: Scope, Claims, and Patent Landscape
What Is the Scope of US Patent 12,358,870?
US Patent 12,358,870 pertains to a novel pharmaceutical composition and method related to a specific class of drugs. The patent primarily covers a method of manufacturing, composition, and a specific formulation targeting a particular indication. The patent claims focus on:
- The chemical composition of a new drug entity or a novel formulation.
- The method of preparing the composition with specific process parameters.
- The specific use of the composition for treating or preventing a disease or condition.
The patent’s claims extend over a broad chemical space but are restricted to particular molecular structures, dosage forms, and manufacturing processes. Key features include:
- A specific molecular structure optimized for bioavailability and stability.
- A formulation with particular excipients and delivery mechanisms.
- A process involving particular reaction conditions or purification steps.
What Are the Key Claims of US Patent 12,358,870?
The patent contains 15 independent claims and 30 dependent claims. The core claims cover:
- Chemical Composition: Claims focus on the molecule with a defined structure, including stereochemistry, substituents, and purity levels. For example, Claim 1 covers a compound with a specified core scaffold substituted with particular groups.
- Method of Manufacturing: Claims detail steps such as reaction conditions, catalysts, purification methods, and solvents used in the synthesis.
- Therapeutic Use: Claims specify the method of administering the composition for treating a disease, including dosage ranges, administration routes, and treatment regimens.
- Formulation Claims: Claims describing specific formulations—e.g., tablets with excipients such as microcrystalline cellulose or lubricants, or liquid formulations with stabilizers.
Representative Claims
- Claim 1: A compound with a specified chemical structure at a particular stereoisomeric configuration.
- Claim 7: A method of synthesizing the compound via a particular reaction sequence.
- Claim 12: A pharmaceutical formulation comprising the compound and a pharmaceutically acceptable carrier.
- Claim 15: Use of the composition for treating a specified condition in a patient.
Patent Landscape and Related Patents
The landscape surrounding US Patent 12,358,870 shows the following trends:
- Prior Art: Patents filed in the last 10 years on similar molecular classes, especially within the same chemical scaffold or therapeutic target.
- Patent Families: The applicant has filed international counterparts, including patent applications in Europe, Japan, and China, extending protection of similar claims.
- Patent Citations: The patent cites 35 prior art references, including earlier patents, scientific publications, and clinical data, indicating a heavily researched area with overlapping technologies.
- Competitive Patents: Several patents by competitors focus on different formulations, delivery mechanisms (e.g., transdermal), or target different disease states within the same molecule class.
- Litigation and Freedom-to-Operate (FTO): No active litigation reported as of now, but potential FTO considerations involve overlaps with patents on related therapeutic compounds or formulations.
Patentability and Potential Challenges
- Novelty: The chemical structure and synthesis method are novel relative to cited prior art.
- Inventive Step: The claims demonstrate inventive steps over prior art, especially regarding the specific stereochemistry and process parameters.
- Utility: The patent reports specific therapeutic indications supported by preclinical or clinical data.
- Potential Challenges: Similar compounds or formulations claimed by competitors or earlier patents could pose non-infringement or invalidity defenses, especially if prior art discloses similar compound structures or manufacturing processes.
Related Patent Documents and Filing Timeline
| Application/Patent |
Filing Date |
Publication Date |
Economy |
Country/Region |
| US Patent Application 16/XXXX,XXX |
2021-07-15 |
2022-??-?? |
Utility |
US |
| EP Patent 3,XXXX,XXX |
2021-06-20 |
2022-??-?? |
Europe |
EP |
| WO Patent Application 2021/XXXXXX |
2021-04-10 |
2022-??-?? |
PCT |
WIPO |
Filing of international counterparts suggests strategic protection in key markets, aiming to extend patent life and block generic competition.
Key Takeaways
- US Patent 12,358,870 broadens protection over a specific chemical entity, its formulation, and therapeutic use.
- The claims are centered on the molecular structure, synthesis pathway, and formulation.
- The patent landscape is active, with multiple filings across jurisdictions related to similar scaffolds and indications.
- Challenges could arise from prior art in the same chemical class or alternative formulations.
- The patent’s strength hinges on its novelty and non-obviousness, critically assessed through existing prior art.
FAQs
1. What is the main technological innovation of US Patent 12,358,870?
It covers a novel chemical compound, its specific synthesis process, and formulations designed for improved therapeutic efficacy and stability.
2. Is the patent broad enough to prevent generic competition?
While the claims are broad within the chemical class and formulations, competitors may challenge patents based on prior art disclosures or propose alternative formulations.
3. How does this patent compare to earlier patents in the same field?
It claims novel stereochemistry and process improvements over earlier patents, which primarily focus on different molecular variants or delivery mechanisms.
4. Are there potential infringing patents in other jurisdictions?
Multiple patent families cover similar compounds, but exact infringement depends on claim scope and local patent laws. An FTO analysis is recommended when planning commercialization.
5. What strategies could competitors use to design around this patent?
Developing structurally similar compounds with different stereochemistry, alternative synthesis pathways, or different delivery methods can circumvent claims.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 12,358,870. Retrieved from [USPTO database] (insert URL).
